Please log in to see the full text of this API!

Fluoxetine

  • Synonyms: Lilly 110140
  • ATC: N06AB03
  • Use: Lorem  Lorem 
  • Chemical name: Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam
  • Formula: Lorem ipsum dolor sit amet,
  • MW:309.33 g/mol
  • CAS-RN:54910-89-3
  • InChI Key:RTHCYVBBDHJXIQ-UHFFFAOYSA-N
  • InChI:InChI=1S/C17H18F3NO/c1-​21-​12-​11-​16(13-​5-​3-​2-​4-​6-​13)​22-​15-​9-​7-​14(8-​10-​15)​17(18,​19)​20/h2-​10,​16,​21H,​11-​12H2,​1H3
  • LD50:464 mg/kg (M, p.o.);
    825 mg/kg (R, p.o.)

Derivatives

    monohydrochloride

  • Use:
  • Formula: Lorem ipsum dolor sit amet,
  • MW:345.79 g/mol
  • CAS-RN:59333-67-4
  • LD50:100 mg/kg (M, i.p.)

Substance Classes

Synthesis Path


























Substances Referenced in Synthesis Path

CAS-RN Formula Chemical Name CAS Index Name
98-86-2 C8H8O acetophenone Ethanone, 1-phenyl-
106-95-6 C3H5Br allyl bromide 1-Propene, 3-bromo-
100-51-6 C7H8O benzyl alcohol Benzenemethanol
70097-65-3 C14H11F3O benzyl 4-(trifluoromethyl)phenyl ether Benzene, 1-(phenylmethoxy)-4-(trifluoromethyl)-
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem
Lorem Lorem Lorem Lorem

Trade Names

Country Trade Name Vendor Annotation
D Lorem Lorem ,1990
Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem ipsum dolor
F Lorem Lorem
Lorem Lorem
GB Lorem Lorem
I Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem Lorem
USA Lorem Lorem
Lorem Lorem
Lorem Lorem
Lorem ipsum
(wfm = withdrawn from market)

Formulations

  • Loremipsumdolorsitamet,consetetursadipscingelitr,seddiamnonumyeirmodtemporinvidunt

References

    • a DE 9 999 999 (Lilly; appl. 3.1.1975; USA-prior. 10.1.1974).
    •  US 9 999 999 (Lilly; 19.4.1977; USA-prior. 10.1.1974).
    •  US 9 999 999 (Lilly; 18.3.1980; USA-prior. 15.9.1976).
    •  US 9 999 999 (Lilly; 2.2.1982; USA-prior. 10.1.1974).
    •  US 9 999 999 (Lilly; 22.4.1986; USA-prior. 24.10.1983, 25.1.1978, 10.1.1974).
    • b US 9 999 999 (Laporte Organics; USA-prior. 7.7.1997).
    • c ES 9 999 999 (Lilly; appl. 3.8.1995).
    • d US 9 999 999 (Albemarle Corp.; USA-prior. 25.7.1997).
    • e ES 999 999 (Lilly; appl. 24.7.1995).
    • f EP 999 999 (Teva Pharm.; appl. 6.8.1992; IL-prior. 27.8.1991).
  • alternative synthesis:

    • EP 999 999 (Orion; appl. 1.3.1990; FI-prior. 3.3.1989).
    • EP 999 999 (E. Magnone; appl. 8.1.1990; I-prior. 10.1.1989).
    • WO 9 999 999 (Albemarle Corp.; appl. 4.8.1998; USA-prior. 4.8.1997).
    • WO 9 999 999 (Albemarle Corp.; appl. 12.6.1998; USA-prior. 12.6.1997).
    • ES 9 999 999 (Almirall Prodesfarma; 16.10.1998; appl. 14.6.1996).
    • EP 999 999 (Teva Pharm.; appl. 6.8.1992; IL-prior. 27.8.1991).
    • EP 999 999 (Pliva D.; appl. 4.2.1994; HR-prior. 5.2.1993).
    • ES 9 999 999 (Lilly; prior. 28.7.1995).
    • ES 9 999 999 (Lilly; prior. 24.7.1995).
    • ES 9 999 999 (Lilly; prior. 29.6.1995).
    • WO 9 999 999 (Egis Gyogyszergyar; appl. 10.9.1997; HU-prior. 10.9.1996).
    • US 9 999 999 (Albemarle Corp.; 2.6.1998; appl. 25.7.1996).
    • ES 9 999 999 (Lilly S. A.; 16.9.1997; appl. 3.8.1995).
    • ES 9 999 999 (Lilly; 16.9.1997; appl. 19.9.1995).
  • synthesis of enantiomers:

    • US 9 999 999 (H. C. Brown; 21.8.1990; prior. 12.6.1989, 30.3.1988).
    • US 9 999 999 (Aldrich; 17.4.1990; prior. 12.6.1989, 30.3.1988).
    • US 9 999 999 (Aldrich; 17.4.1990; prior. 12.6.1989, 30.3.1988).
  • fluoxetine chiral process from benzoylpropionic acid:

    • US 9 999 999 (Sepacor Inc.; appl. 22.6.1998).
  • treatment of nicotine withdrawal symptoms:

    • US 9 999 999 (W. E. Hapworth; 10.7.1990; appl. 17.2.1989).
  • treatment of appetite and mood disturbances:

    • WO 9 999 999 (MIT; appl. 21.10.1988; USA-prior. 15.9.1988; 22.10.1987).
  • antidiabetic combination:

    • EP 999 999 (Lilly; appl. 29.4.1988; USA-prior. 4.5.1987).
  • pharmaceutical formulation:

    • EP 999 999 (Lilly; appl. 17.7.1995; E-prior. 20.7.1994).
  • memory improvement:

    • US 9 999 999 (Lilly; 3.3.1987; prior. 7.10.1985, 21.6.1985).
  • solid oral composition:

    • ES 9 999 999 (Lilly; appl. 29.9.1995).
  • analgesic compositions:

    • EP 999 999 (Lilly; appl. 20.2.1986; USA-prior. 25.2.1985, 25.7.1986).
    • EP 999 999 (Lilly; appl. 20.2.1986; USA-prior. 25.2.1985).
  • treatment of anxiety:

    • EP 999 999 (Lilly; appl. 6.4.1984; USA-prior. 8.4.1983).
  • novel transdermal formulations:

    • WO 9 999 999 (Alza Corp.; appl. 15.7.1997; USA-prior. 15.7.1996).
  • pharmaceutical formulations:

    • EP 999 999 (Lilly; appl. 17.7.1995; E-prior. 20.7.1994).
  • low dose tablet:

    • US 9 999 999 (Pentech Pharm.; 3.11.1998; appl. 22.7.1996; USA-prior. 22.7.1996).
Cookie-Einstellungen